Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

M-CSF attenuates severity of chronic GVHD after unrelated BMT

Bone Marrow Transplantation volume 47, pages 426–429 (2012)Cite this article

Abstract

To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55–0.94; P=0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl J Med 1999; 341: 14–21.

    Article  CAS  PubMed  Google Scholar 

  2. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  3. Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant 1996; 2: 86–92.

    CAS  PubMed  Google Scholar 

  4. Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001; 98: 3868–3870.

    Article  CAS  PubMed  Google Scholar 

  5. Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315–323.

    CAS  PubMed  Google Scholar 

  6. Masaoka T, Shibata H, Ohno R, Katoh S, Harada M, Motoyoshi K et al. Double-blind test of human urinary macrophage colony-stimulating factor for allogeneic and syngeneic bone marrow transplantation: effectiveness of treatment and 2-year follow-up for relapse of leukaemia. Br J Haematol 1990; 76: 501–505.

    Article  CAS  PubMed  Google Scholar 

  7. Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997; 15: 2954–2965.

    Article  CAS  PubMed  Google Scholar 

  8. Li G, Kim YJ, Broxmeyer HE . Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10(high)IL-12absent dendritic cells with tolerogenic potential. J Immunol 2005; 174: 4706–4717.

    Article  CAS  PubMed  Google Scholar 

  9. Kwan WH, Boix C, Gougelet N, Fridman WH, Mueller CG . LPS induces rapid IL-10 release by M-CSF-conditioned tolerogenic dendritic cell precursors. J Leukoc Biol 2007; 82: 133–141.

    Article  CAS  PubMed  Google Scholar 

  10. Hashimoto D, Chow A, Greter M, Leboeuf M, Ginhoux F, Teshima T et al. Pre-transplant CSF-1 therapy expands the recipient macrophage pool and modulates graft versus host disease after allogeneic hematopoietic cell transplantation. Blood 2010; 116: abstract 242.

    Google Scholar 

  11. Sakata N, Yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K . Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001; 27: 1153–1161.

    Article  CAS  PubMed  Google Scholar 

  12. Barak V, Levi-Schaffer F, Nisman B, Nagler A . Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 1995; 17: 169–173.

    Article  CAS  PubMed  Google Scholar 

  13. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E . Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59–65.

    Article  CAS  PubMed  Google Scholar 

  14. Korholz D, Kunst D, Hempel L, Sohngen D, Heyll A, Bonig H et al. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 691–695.

    Article  CAS  PubMed  Google Scholar 

  15. Smith W, Feldmann M, Londei M . Human macrophages induced in vitro by macrophage colony-stimulating factor are deficient in IL-12 production. Eur J Immunol 1998; 28: 2498–2507.

    Article  CAS  PubMed  Google Scholar 

  16. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.

    CAS  PubMed  Google Scholar 

  17. Sugimoto K, Narimatsu H, Kawase T, Iida H, Watanabe M, Kohno A et al. Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. Bone Marrow Transplant 2008; 41: 729–736.

    Article  CAS  PubMed  Google Scholar 

  18. Narimatsu H, Miyakoshi S, Yamaguchi T, Kami M, Matsumura T, Yuji K et al. Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1,072 patients in Japan. Blood 2008; 112: 2579–2582.

    Article  CAS  PubMed  Google Scholar 

  19. Saito S, Motoyoshi K, Ichijo M, Saito M, Takaku F . High serum human macrophage colony-stimulating factor level during pregnancy. Int J Hematol 1992; 55: 219–225.

    CAS  PubMed  Google Scholar 

  20. Ikeno K, Koike K, Fukuromoto T, Shimizu T, Nagatomo M, Komiyama A . Increased macrophage-colony stimulating factor levels in neonates with perinatal complications. Early Hum Dev 1996; 46: 229–237.

    Article  CAS  PubMed  Google Scholar 

  21. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the help of the JMDP transplant and donor centers in providing data for this study, and the JMDP staff for their assistance.

Author information

Authors and Affiliations

  1. Division of Hematology, National Defense Medical College, Tokorozawa, Japan

    F Kimura, K Sato & K Motoyoshi

  2. Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

    H Akiyama

  3. Department of Hematology, Meitetsu Hospital, Nagoya, Japan

    H Sao

  4. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    S Okamoto

  5. Research Institute for Artificial Organs, Transplantation and Gene Therapy, Sapporo, Japan

    N Kobayashi

  6. Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan

    M Hara

  7. Osaka Medical Centre and Research Institute for Maternal and Child Health, Osaka, Japan

    K Kawa

Authors
  1. F Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Sao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Kawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Motoyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for The Japan Marrow Donor Program

Corresponding author

Correspondence to F Kimura.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimura, F., Sato, K., Akiyama, H. et al. M-CSF attenuates severity of chronic GVHD after unrelated BMT. Bone Marrow Transplant 47, 426–429 (2012). https://doi.org/10.1038/bmt.2011.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.90

Keywords

Search

Advanced search

Quick links